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Abstract To study whether the effects of prognostic
factors associated with the occurrence of distant metastases
(DM) at primary diagnosis change after the incidence of
loco-regional recurrences (LRR) among women treated for
invasive stage I or II breast cancer. The study population
consisted of 3,601 women, enrolled in EORTC trials
10801, 10854, or 10902 treated for early-stage breast
cancer. Data were analysed in a multivariate, multistate
model by using multivariate Cox regression models,
including a state-dependent covariate. The presence of a
LRR in itself is a signiﬁcant prognostic risk factor (HR:
3.64; 95%-CI: 2.02–6.5) for the occurrence of DM. Main
prognostic risk factors for a DM are young age at diagnosis
(B40: HR: 1.79; 95%-CI: 1.28–2.51), larger tumour size
(HR: 1.58; 95%-CI: 1.35–1.84) and node positivity (HR:
2.00; 95%-CI: 1.74–2.30). Adjuvant chemotherapy is pro-
tective for a DM (HR: 0.66; 95%-CI: 0.55–0.80). After the
occurrence of a LRR the latter protective effect has dis-
appeared (P = 0.009). The presence of LRR in itself is a
signiﬁcant risk factor for DM. For patients who are at risk
of developing LRR, effective local control should be the
main target of therapy.
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Introduction
Breast-conserving surgery is associated with a higher risk
of loco-regional recurrences (LRR), as compared to mas-
tectomy [1–5]. However, the impact of LRR on overall
survival has not been demonstrated in trials which
randomized between breast-conserving therapy and mas-
tectomy [6–8]. A common explanation of these data is that
the most important therapy in breast cancer is effective
systemic therapy. Another explanation is that local control
is a very important in the treatment of breast cancer, but
that these trials did not have the power to study the impact
of LRR on overall survival, due to the low incidence of
LRR as compared to distant metastases (DM). It is rea-
sonable to suppose that there is a group of LRR after
primary treatment that are not associated with DM or death
and that are potentially curable. In these recurrences early
diagnosis can prevent the development of distant metasta-
sis [9]. In addition, in a recent meta-analysis it was found
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cancer-speciﬁc death [10]. On this basis it might be useful
if at the time of primary treatment we could identify
prognostic risk factors associated with an increased risk of
developing LRR followed by DM. Therefore, we studied
whether the effects of prognostic risk factors associated
with DM at primary diagnosis change after the incidence of
LRR.
The aim of this analysis was to study the effect of
prognostic factors known at primary diagnosis on the
occurrence of DM. The effects were estimated for patients
without any occurrence of LRR and for patients after the
occurrence of LRR. In this way we were able perform a
formal test on the equality of these effects, and to test the
effect of LRR on the occurrence of DM. To do this, using a
multivariate multistate model, we reanalysed the data of
3,601 patients with early-stage breast cancer who were
surgically recruited in three EORTC trials (studies 10801,
10854 and 10902). Using this approach, we discerned three
outcomes (no recurrence, LLR and DM) over the course of
the disease after primary surgery, and using one model we
studied the effect of all prognostic factors for each
outcome.
Methods
Selection of trials and patients
Patients were selected from trials that randomized early-
stage breast cancer patients. The European Organisation for
Research and Treatment has conducted several large ran-
domized phase III trials concerned with the optimal
management of breast cancer in patients with stage I or II
breast cancer. A total number of 4,395 breast cancer
patients were enrolled for these trials, EORTC trial 10801,
10854 and 10902. Patients treated with preoperative che-
motherapy (n = 377), patients not eligible for the study
(due to false inclusion or severe protocol violation,
n = 88), patients with stage III breast cancer (n = 238),
and patients without full information on all covariates
(n = 91) were excluded from the analysis. A summary of
the 3,601 patients included is provided in Table 1. For a
short summary of the events and the median follow-up
times, see Table 2. A brief description of these trials
follows.
EORTC trial 10801 (1980–1986, median follow-up
13.4 years) was conducted in order to assess the safety of
Table 1 Characteristics
of patients, for all studies
and total
Characteristics Study Total
N (%)
10801 10854 10902
N (%) N (%) N (%)
Age at diagnosis
C50 530 (61.8) 1,512 (60.1) 93 (40.8) 2,135 (59.3)
40–50 244 (28.5) 720 (28.6) 96 (42.1) 1,060 (29.4)
\40 83 (9.7) 284 (11.3) 39 (17.1) 406 (11.3)
Tumour size
\2 cm 167 (19.5) 801 (31.8) 38 (16.7) 1,006 (27.9)
2–5 cm 690 (80.5) 1,715 (68.2) 190 (83.3) 2,595 (72.1)
Nodal state
Node-negative 501 (58.5) 1,360 (54.1) 83 (36.4) 1,944 (54.0)
Node-positive 356 (41.6) 1,156 (45.9) 145 (63.6) 1,657 (46.0)
Surgical therapy
Mastectomy 413 (48.3) 1,030 (40.9) 162 (71.1) 1,605 (44.6)
Breast-conserving therapy 444 (51.7) 1,486 (59.1) 66 (28.9) 1,996 (55.4)
Perioperative chemotherapy
No 857 (100) 1,261 (50.1) 228 (100) 2,346 (65.2)
Yes – 1,255 (49.9) – 1,255 (34.8)
Adjuvant chemotherapy
No 708 (82.6) 2,061 (81.9) – 2,769 (76.9)
Yes 149 (17.4) 455 (18.1) 228 (100) 832 (23.1)
Adjuvant radiotherapy
No 242 (28.3) 533 (21.2) 83 (36.4) 858 (23.8)
Yes 615 (71.7) 1,983 (78.8) 145 (63.6) 2,743 (76.2)
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123breast-conserving treatment. In this trial, patients were
randomized between breast-conserving surgery combined
with radiotherapy, and modiﬁed radical mastectomy. Six
cycles of adjuvant chemotherapy with cyclophosphamide
100 mg/m
2 given orally on days 1–14, methotrexate
40 mg/m
2 given intravenously on days 1 and 8, and
5-ﬂuorouracil 600 mg/m
2 given intravenously on days 1
and 8, were indicated for all patients under the age of 55
with positive nodes. In this study, 902 patients were ran-
domized [2, 11, 12].
EORTC trial 10854 (1986–1991, median follow-up
10.8 years) studied the question whether one course of
perioperative chemotherapy given directly after surgery
yields better results in terms of treatment outcome than
surgery alone. Perioperative chemotherapy consisted of
one single course of doxorubicin 50 mg/m
2, 5-ﬂuorouracil
600 mg/m
2 and cyclophosphamide 600 mg/m
2 (FAC),
administered intravenously within 36 h of surgery. It was
recommended that axillary lymph node-positive premeno-
pausal patients in the perioperative chemotherapy group
receive an extra ﬁve cycles of cyclophosphamide, metho-
trexate and 5-ﬂuorouracil (CMF). Node-positive patients
younger than 50 years who did not receive perioperative
chemotherapy were advised to take one conventional
course of FAC followed by ﬁve cycles of CMF after sur-
gery. Patients were stratiﬁed for breast-conserving therapy
and modiﬁed radical mastectomy. Prolonged adjuvant
systemic treatment was left to the discretion of the local
investigators. The trial included 2,795 patients [13–15].
EORTC trial 10902 (1991–1999, median follow-up
6.1 years) was set up to determine the value of preoperative
chemotherapy. Patients were randomized to receive four
cycles of chemotherapy either before or after surgery.
Chemotherapy consisted of four cycles of 5-ﬂuorouracil
600 mg/m
2, epirubicin 60 mg/m
2 and cyclophosphamide
600 mg/m
2 (FEC) administered intravenously at 3-week
intervals. In the preoperative chemotherapy group, surgical
therapy followed within 4 weeks of the fourth course of
chemotherapy. In the postoperative chemotherapy group,
the ﬁrst cycle was given within 36 h after surgery. A total
number of 698 patients were randomized [16].
Assessments and statistical methods
We modelled breast cancer disease progression as a mul-
tistate model. In this approach, transitions are assessed
during the course of the disease and prognostic factors for
each transition are studied [17, 18]. In our model there are
three possible outcomes or states in which a patient may be
at any time (see Fig. 1). After surgery, a patient may be
without any recurrences due to the primary breast cancer, a
patient may experience a LRR, or a patient may develop
metastatic breast cancer disease. The directions of the
arrows in Fig. 1 indicate the transitions between the three
states that are logically possible. Transition 1 indicates the
transition from ‘without any recurrence’ to ‘LRR’;
transition 2 indicates the transition from ‘without any
recurrence’ to ‘DM’; transition 3 indicates the transition
from ‘LRR’ to ‘DM’.
A LRR was deﬁned as any recurrence in the breast, the
chest wall, the axillary or supraclavicular lymph nodes. In
Table 2 Follow-up and events for the patients included in this analysis per study and in total
Study Total
10801 10854 10902
Total number of patients 857 2,516 228 3,601
Events N (%) N (%) N (%) N (%)
Loco-regional recurrences 78 (9.1) 221 (8.7) 11 (4.8) 310 (8.6)
Distant metastases
All distant metastases 330 (38.5) 833 (33.1) 61 (26.7) 1,224 (40.0)
Distant metastases after loco-regional recurrences 36 (4.2) 90 (3.5) 3 (1.3) 129 (3.5)
Median (range) follow-up time in years for the patients
included in this analysis
11.9 (0.6–17.4) 10.2 (0.2–14.2) 5.3 (0.6–9.5) 10.2 (0.2–17.4)
After surgery 
without any 
recurrence
Isolated
loco-regional
recurrence
Distant
metastasis
13
2
Fig. 1 Breast cancer disease progression as a multistate model. There
are three possible states in which a patient may be at any time. After
surgery, without any recurrence, loco-regional recurrence (LRR),
distant metastasis (DM). Arrow 1 indicates the transition from
‘without any recurrence’ to ‘LRR’. Arrow 2 indicates the transition
from ‘without any recurrence’ to ‘DM’. Arrow 3 indicates the
transition from ‘LRR’ to ‘DM’
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123patients experiencing LRR after the diagnosis of DM, the
LRR was not used as outcome. In the analyses, all primary
sites of LRR were combined into one group of recurrences.
Death was not considered as a separate outcome because
all metastatic breast cancer disease will inevitably lead to
death. In addition, the database did not allow us to discern
breast cancer-speciﬁc death from other causes of death.
The following characteristics were considered for each
transition: age at diagnosis (\40, 40–50, C50), tumour size
(B2 cm, 2–5 cm), axillary nodal status (0, C1), surgical
therapy (mastectomy, breast-conserving therapy), periop-
erative chemotherapy (yes, no), adjuvant chemotherapy
(yes, no), and adjuvant radiotherapy (yes, no), see Table 1.
The values for all characteristics were based on clinical
observations.
The beginning of follow-up corresponded to the time of
randomization (close to the date of surgery). The end of
follow-up corresponded to the incidence of distant metas-
tases or the last date of follow-up (due to death, being lost
to follow-up, or end of study).
The prognostic effect of all independent variables was
measured by adjusted hazard ratios (HR) with 95% conﬁ-
dence intervals (95%-CI). To control for unmeasured
possible differences in study populations, study group was
added as a factor in all models. All analyses were per-
formed with SPSS12.01. A signiﬁcance level of 0.05 was
used.
To estimate the adjusted hazard ratios for the transitions
from surgery to LRR, a multivariate Cox proportional-
hazard regression model was performed (results in Table 3,
column 1).
Because we wanted to compare the transition from
surgery to DM with the transition from LRR to DM, a
multivariate Cox regression proportional-hazard model,
including a time-dependent covariate, was performed to
estimate the adjusted hazard ratios in tests related to these
two transitions. As this time-dependent covariate refers to a
state, it is further named a state-dependent covariate.
To estimate the adjusted hazard ratios for distant
metastases after surgery, the state-dependent covariate was
Table 3 Characteristics of all patients with respect to parameter estimates related to each transition
Characteristics Transition 1: from
surgery to LRR
Transition 2: from
surgery to DM
Transition 3: from
LRR to DM
P-values for testing transition
2 versus transition 3
Numbers at risk 3,601 3,601 310
Numbers of events 310 1,115 129
Age at diagnosis P 5 0.001 P < 0.001 P = 0.82 0.17
C5 0 111
40–50 1.42 (1.09–1.85) 0.95 (0.81–1.11) 0.94 (0.62–1.41)
\40 1.79 (1.28–2.51) 1.45 (1.19–1.76) 0.85 (0.51–1.42)
Tumour size
\2 c m 111
2–5 cm 1.07 (0.83–1.37) 1.58 (1.35–1.84) 1.12 (0.74–1.69) 0.19
Nodal state
Node-negative 1 1 1
Node-positive 1.17 (0.89–1.55) 2.00 (1.74–2.30) 1.69 (0.13–2.53) 0.49
Surgical therapy
Mastectomy 1 1 1
Breast-conserving therapy 2.26 (1.63–3.12) 0.93 (0.81–1.07) 1.22 (0.70–2.11) 0.42
Perioperative chemotherapy
N o 111
Yes 0.68 (0.52–0.90) 0.95 (0.82–1.09) 1.20 (0.81–1.77) 0.28
Adjuvant chemotherapy
N o 111
Yes 0.82 (0.57–1.19) 0.66 (0.55–0.80) 1.35 (0.83–2.21) 0.009
Adjuvant radiotherapy
N o 111
Yes 0.59 (0.41–0.84) 1.05 (0.88–1.25) 1.27 (0.70–2.32) 0.67
Loco-regional recurrence present 3.64 (2.02–6.55)
Time to loco-regional recurrence 1.44 (0.99–2.10)
Bold values refer to signiﬁcant values
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1230 for patients without LRR. For patients with a LRR, this
state-dependent covariate was 0 before the incidence of a
LRR, and became 1 after the incidence of a LRR. This
model allows an interpretation of the effects of the covar-
iates as adjusted hazard ratios for DM without any LRR
(results in Table 3, column 2).
To estimate the adjusted hazard ratios for DM after
LRR, the state-dependent covariate was 1 for patients
without a LRR. For patients with a LRR, it was 1 before the
incidence of a LRR and became 0 afterwards, allowing the
interpretation of the effects of the covariates as adjusted
hazard ratios for DM after a LRR (results in Table 3,
column 3).
In these two models, the state-dependent covariate itself
indicates the prognostic risk of DM after LRR. The inter-
action of the state-dependent covariate with the other
covariates provides a test of the changes in the effects of
prognostic factors after LRR [18].
All prognostic factors were included, as well as the
interaction of the prognostic factors with a state-dependent
covariate. Finally, the model was extended with a second
time-dependent covariate. This time-dependent covariate
was 0 before the incidence of a LRR, and equivalent to the
time (in years from randomization) of LRR. Incorporation
of this second time-dependent covariate allowed us to
study changes in the hazard ratio that might be related to
the timing of the LRR.
Results
A LRR was observed in 310 (8.6%) of the patients, 1,224
(40.0%) of the patients had DM without LRR, while 129
(3.5%) of the patients had DM after LRR (Table 2).
The main prognostic risk factors for LRR were breast-
conserving therapy (HR: 2.26; 95%-CI: 1.63–3.12) and
young age at diagnosis (\40: HR: 1.79; 95%-CI: 1.28–2.51;
40–50: HR: 1.42; 95%-CI: 1.09–1.85) (Table 3). Perioper-
ative chemotherapy (HR: 0.68; 95%-CI: 0.52–0.90) and
adjuvant radiotherapy (HR: 0.59; 95%-CI: 0.41–0.84)
lowered the risk of LRR.
Young age at diagnosis (\40: HR: 1.45; 95%-CI: 1.19–
1.76), larger tumour size (HR: 1.58; 95%-CI: 1.35–1.84),
and positive nodal state (HR: 2.00; 95%-CI: 1.74–2.30)
were signiﬁcant prognostic risk factors for DM. Adjuvant
chemotherapy (HR: 0.66; 95%-CI: 0.55–0.80) lowered the
risk of DM.
The presence of a LRR in itself was a signiﬁcant
prognostic risk factor (HR: 3.64; 95%-CI: 2.02–6.55) for
DM. The longer time until the LRR was a borderline sig-
niﬁcant prognostic factor (HR: 1.44; 95%-CI: 0.99–2.10).
When testing the equality of the HRs related to the
transition from surgery to DM and those related to the
transition from LRR to DM, the HR for adjuvant chemo-
therapy was signiﬁcantly different, indicating that after
primary surgery adjuvant chemotherapy was statistically
signiﬁcant associated with a favourable prognostic effect
on the incidence of DM, whereas after the incidence of the
LRR primary adjuvant chemotherapy was no more statis-
tically signiﬁcant associated with an unfavourable
prognosis (P-value for difference in the prognostic role of
primary adjuvant chemotherapy: 0.009).
Discussion
We studied whether the effects of prognostic risk factors
associated with DM at primary diagnosis change after the
incidence of LRR among women treated for invasive stage I
or II breast cancer. The presence of LRR in itself is a sig-
niﬁcant prognostic risk factor (HR: 3.64; 95%-CI: 2.02–6.5)
for the occurrence of DM. Other main prognostic risk fac-
tors for DM are young age at diagnosis (B40: HR: 1.79;
95%-CI: 1.28–2.51), larger tumour size (HR: 1.58; 95%-CI:
1.35–1.84) and node positivity (HR: 2.00; 95%-CI: 1.74–
2.30). Adjuvant chemotherapy is protective for DM (HR:
0.66; 95%-CI: 0.55–0.80). After the occurrence of LRR this
protective effect is no longer present (P = 0.009).
Young age, larger tumour size and nodal status are the
most important prognostic factors for the occurrence of
DM [for example, 19, 20]. Young age and breast-con-
serving therapy are often mentioned as risk factors for the
incidence of LRR [for example, 21–23]. Other studies also
report that patients with a LRR are at an increased risk of
developing DM as compared to patients who develop no
LRR [for example, 24–27]. We found that time from sur-
gery until the loco-regional recurrence was not a signiﬁcant
prognostic factor, whereas in the literature there are many
indications that earlier loco-regional recurrences are asso-
ciated with worse patient outcome [28–30].
The effect of LRR on the occurrence of DM has been
debated for decades [31]. On the one hand there is the view
that breast cancer is a local disease that spreads over time
to develop DM [32]. On the other hand there is the view
that breast cancer is a systemic disease from the outset with
DM present before primary diagnosis [33]. Though it is
clear that the ﬁrst view on the biology of breast cancer is
not correct for all breast cancers, the systemic view is not
entirely correct for all breast cancers either [31]. In this
paper we hypothesised a model that is at least partly based
on the ﬁrst view of distant spread. Our ﬁnding that the
presence of LRR in itself is a signiﬁcant prognostic risk
factor for the occurrence of DM gives some support for this
hypothesis. Other data supporting this hypothesis are
derived from randomized clinical trials demonstrating a
link between local control and overall survival in breast
Breast Cancer Res Treat (2009) 117:401–408 405
123cancer [e.g., 10, 34, 35]. The statistical analysis presented
in this paper is just an argument in the discussion on the
effect of LRR on the occurrence of DM. However, it never
can proof a causal relation.
The current analysis was based on a database of three
trials with complete information on crucial parameters and
long-term follow-up for more than 3,500 patients. The
trials concerned patients treated for early breast cancer, and
the patient, disease and treatment characteristics as well as
the outcomes were registered in a comparable way, which
allowed us to meta-analyse these three studies. Patients
treated with preoperative chemotherapy were excluded
because the pT-size of the tumours of these patients may
not have been comparable to the pT-size of patients with-
out this treatment.
To control for factors such as treatment (e.g., mastec-
tomy versus breast-conserving therapy) only the results of
the multivariate multistate analyses were presented. The
various types of treatment were analyzed as separate
components, due to the fact that in the older studies
included not all patients were treated among the current
pre-deﬁned treatment schemes.
The aim of this analysis was to study the effect of
prognostic factors known at primary diagnosis on the
occurrence of DM. These effects were estimated for
patients without any occurrence of LRR and for patients
after the occurrence of LRR. In this way we were able
perform a formal test on the equality of these effects, and to
test the effect of LRR on the occurrence of DM. One of the
strongest points of the multivariate multistate model
applied in this paper is that all data are summarized in one
model instead of presenting many separate analyses. Pre-
senting many separate analyses will lower the power of the
estimated effects or may result in false positive ﬁndings.
Such an analysis can only be performed on a large cohort
of patients with a long follow-up time. Only in such a
cohort there are enough events of LRR and DM after the
occurrence of LRR. For that reason we chose to analyse
studies with the longest follow-up available.
A shortcoming of this study is that some data recognised
as being related to important prognostic and predictive
factors were missing from the database. Hormonal status
was unknown for most patients, as was the use of
Tamoxifen. Recording the number of positive nodes or a
more detailed T stage, grade, margin status and lympho-
vascular invasion was not part of the protocol in these
EORTC studies, so we were not able to include this
information in our meta-analysis. This can be considered a
limitation of our study because these factors allow the
breast cancers to be further categorized with respect to
risks which might inﬂuence the occurrence of LRR. Tai-
lored systemic treatment making use of ER and PR
receptors and HER2 is now state of the art [10]. Only the
newer studies will include the newer predictive and prog-
nostic factors, but these studies will not allow us to perform
such long-term analyses due to their shorter follow-up.
The main ﬁnding of this study is that patients with a
LRR have a more than three times increased risk of
developing DM as compared to patients who develop no
LRR. Due to a lowering incidence of LRR, especially after
adjuvant therapy in node negative patients, this might be an
overestimation of the effect of LRR on the occurrence of
DM after LRR [36]. However, in a recent meta-analysis of
the long-term effects of LRR on breast cancer mortality, it
was concluded that for every four LRR that were avoided,
one breast cancer death over the next 15 years could be
avoided, and that this should reduce 15-year overall mor-
tality [10]. Our study conﬁrms these ﬁndings, as we found a
strong association between the occurrence of a loco-
regional recurrence and a distant metastasis (HR: 3.64;
95%-CI: 2.02–6.55).
This study again stresses the point that breast-conserving
therapy is a risk factor for local recurrence and that patients
with a loco-regional recurrence are at an increased risk of
developing distant metastases as compared to patients who
develop no loco-regional recurrence. This is also reported in
other studies [for example, 25, 26]. Young patients are more
at risk of developing local recurrences than older patients.
Treatment selection at time of diagnosis, especially in
young patients, should therefore focus on improvement of
local control. Improvement of systemic treatment regimens
will improve this local control, as will the provision of
systemic adjuvant therapy [for example, 10, 37, 38]o ra n
increase in the radiation dose on the tumour bed [for
example, 36, 39].
A prediction of the risk of LRR at the time of diagnosis
can guide treatment decisions and lead to optimal local
control. These prognostic risk factors could be incorporated
into a web-based tool and guide primary treatment choices,
similarly to the web-based models that guide the optimal
choice of adjuvant therapy by making use of prognostic
factors for DM in predicting the outcome of early breast
cancer (http://www.adjuvantonline.com/). Breast cancer
before the age of 50 and breast-conserving therapy should
be included in such a model as risk factors for the incidence
of LRR. To build such a system, large databases with long
follow-up times are needed.
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